WO2010075863A1 - Arginase inhibitors for the treatment of depression - Google Patents
Arginase inhibitors for the treatment of depression Download PDFInfo
- Publication number
- WO2010075863A1 WO2010075863A1 PCT/EE2008/000027 EE2008000027W WO2010075863A1 WO 2010075863 A1 WO2010075863 A1 WO 2010075863A1 EE 2008000027 W EE2008000027 W EE 2008000027W WO 2010075863 A1 WO2010075863 A1 WO 2010075863A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- depression
- arginase
- treatment
- prevention
- compound
- Prior art date
Links
- 102000004452 Arginase Human genes 0.000 title claims abstract description 52
- 108700024123 Arginases Proteins 0.000 title claims abstract description 52
- 239000003112 inhibitor Substances 0.000 title description 20
- 208000020401 Depressive disease Diseases 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 54
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 claims abstract description 33
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 claims abstract description 30
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 29
- 230000002265 prevention Effects 0.000 claims abstract description 29
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000013543 active substance Substances 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 241000124008 Mammalia Species 0.000 claims description 5
- 238000011835 investigation Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 26
- 230000000694 effects Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 13
- 229960003104 ornithine Drugs 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 8
- 230000009182 swimming Effects 0.000 description 8
- 239000000935 antidepressant agent Substances 0.000 description 7
- 230000003542 behavioural effect Effects 0.000 description 7
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 230000008503 anti depressant like effect Effects 0.000 description 6
- 229940005513 antidepressants Drugs 0.000 description 6
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 5
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000001430 anti-depressive effect Effects 0.000 description 5
- 230000000949 anxiolytic effect Effects 0.000 description 5
- 230000006742 locomotor activity Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 3
- 229930064664 L-arginine Natural products 0.000 description 3
- 235000014852 L-arginine Nutrition 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- -1 Aziridinyl putrescine Chemical compound 0.000 description 2
- FQWRAVYMZULPNK-BYPYZUCNSA-N N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)NO FQWRAVYMZULPNK-BYPYZUCNSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000002113 chemopreventative effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 229960002759 eflornithine Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HFKKMXCOJQIYAH-YFKPBYRVSA-N (S)-2-amino-6-boronohexanoic acid Chemical compound OC(=O)[C@@H](N)CCCCB(O)O HFKKMXCOJQIYAH-YFKPBYRVSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 229940080328 Arginase inhibitor Drugs 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 244000019459 Cynara cardunculus Species 0.000 description 1
- 235000019106 Cynara scolymus Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- KIDHWZJUCRJVML-UHFFFAOYSA-N Putrescine Natural products NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000016520 artichoke thistle Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940112478 crataegus extract Drugs 0.000 description 1
- 239000010108 crataegus extract Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- VLCYCQAOQCDTCN-ZCFIWIBFSA-N α-difluoromethylornithine Chemical compound NCCC[C@@](N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-ZCFIWIBFSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Definitions
- the present invention relates to compositions useful in the therapy of depression and depression-related conditions. More particularly the invention relates to compounds, which exhibit arginase inhibiting activity.
- Arginase (EC Nr 3.5.3.1) is an enzyme, activity of which results in converting the amino acid L-arginine into L-ornithine and urea, being an essential part of the urea cycle.
- L-arginine is also a precursor of NO, a free radical molecule involved in a wide range of biological processes.
- Several compounds useful for the treatment of a variety of diseases and disorders have been also shown as possessing arginase inhibiting activity. E.g.
- arginase inhibitors N(omega)- hydroxy-L-arginine (NOHA), N'-hydroxy-nor-L-arginine (nor-NOHA), 2 (S)-amino-6- boronohexanoic acid (ABH), S- (+)-Amino-6-iodoacetamidohexanoic acid, S- (+)-Amino-5- iodoacetamidopentanoic acid, L-norvaline, or L-HOArg have been shown as a possible means for treatment of asthma, pulmonary hypertension and sickle cell disease (WO/2004/073623 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions).
- L-norvaline is considered to be a potent arginase inhibitor (Rognstad R. Sources of ammonia for urea synthesis in isolated rat liver cells. Biochim Biophys Acta 1977; 496: 249-254; Chang CI, Liao JC, Kuo L. Arginase modulates nitric oxide production in activated macrophages. Am J Physiol 1998; 274: H342-H348).
- Alpha-DFMO is well-known as an inhibitor of ornithine decarboxylase, but is also a potent inhibitor of arginase (Selamnia M, Mayeur C, Robert V, Blachier F.
- Alpha-difluoromethylornithine as a potent arginase activity inhibitor in human colon carcinoma cells. Biochem Pharmacol 1998; 55: 1241-1245.3)
- alfa-DFMO eflornithine, sometimes called "elfornithine
- US6573290 for the treatment or prevention of cancer
- US6258845 DFMO and sulindac combination in cancer chemoprevention
- US4925835 Azridinyl putrescine containing compositions and their uses in treating prostate cancer
- US627741 1 Pubmaceutical formulation containing DFMO for the treatment of cancer.
- Norvaline is an analog of the branched chain amino acid valine and is not present among the 20 common natural amino acid compounds of proteins. It has been used in various combinations in research work being included into peptides, as well as in nutritional compositions, e.g. in WO/2008/067641 (Composition for improving blood flow in working muscles comprising L-arginine, Crataegus extract and artichoke flavonoids). It has been demonstrated, that increased activity of arginase results in a diminished output of NO (Que LG, George SE, Gotoh T, Mori M, Huang YC. Effects of arginase isoforms on NO production by nNOS.
- arginase inhibitors may increase the production of NO.
- NO synthase inhibitors possess antidepressant and anxiolytic like properties (Volke V, Wegener G, Bourin M, Vasar E. Antidepressant- and anxiolytic-like effects of selective neuronal NOS inhibitor l-(2-trifluoromethylphenyl)-imidazole in mice. Behavioural Brain Research 2003; 140: 141-147), arginase inhibitors should have the opposite effect.
- arginase inhibitors possess antidepressant properties.
- arginase inhibitors e.g., L-norvaline and alpha-DFMO are therapeutically promising as antidepressant agents.
- the subjects of the current invention are compounds, which exhibit arginase inhibiting activity (including difluoromethylornithine (DFMO) and L-norvaline, but not limited to them), and which therefore can be used as therapeutically active agents for the treatment and prevention of depression and/or depression-related conditions.
- the compounds inhibiting arginase activity can be difluoromethylornithine (DFMO), L- norvaline, but not limited to them.
- arginase inhibiting compounds as therapeutically active agents for the manufacture of pharmaceutical compositions for human and veterinary application
- pharmaceutical compositions comprising said compounds and pharmaceutically acceptable carrier.
- Representatives of such carriers are generally known in the human and veterinary pharmaceutical field. Examples of such carriers are starch, alginates, stearates, gelatin, lactose, microcrystalline cellulose, etc.
- the pharmaceutical compositions may have any form suitable for its application, for instance they may be in the form of capsule, powder, tablet, solution, suspension, lotion, etc.
- DFMO difluoromethylornithine
- L-norvaline other arginase inhibitors
- compositions comprising difluoromethylornithine (DFMO), L-norvaline or other arginase inhibitors can be used for treatment and/or prevention of depression and/or depression-related conditions.
- DFMO difluoromethylornithine
- L-norvaline or other arginase inhibitors
- a method for identifying compounds suitable for use as therapeutically active agents for treatment and/or prevention of depression and/or depression-related conditions and/or anxiety is disclosed, which comprises determining whether the compound under investigation exhibits arginase inhibiting activity, and if the named compound exhibits arginase inhibiting activity, then the named compound is selected as candidate for a compound suitable for use as therapeutically active agent for treatment and/or prevention the named diseases and/or conditions.
- Also included in the invention is a method for treatment and prevention of depression and/or depression-related conditions, which comprises administering to a mammal suffering from depression and/or depression-related conditions or a mammal supposed to gain depression or depression related disorder a therapeutically effective amount of a compound which exhibits arginase inhibiting activity.
- kit for selecting novel compounds for treatment and/or prevention of depression and/or depression-related conditions comprises at least a means for determining a compound's arginase inhibiting activity by a method known to the person skilled in the art. If arginase inhibiting activity is detected, then the compound is selected for a further screening of its properties as a drug candidate for the treatment and/or prevention of depression and/or depression-related conditions.
- the antidepressant properties of arginase inhibiting agents L-norvaline and DFMO were investigated by means of a set of behavioural tests in animals conventionally employed in pharmacology and generally considered predictive of antidepressant activity in man (Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977; 229: 327-336; Crawley J, Goodwin FK.
- L-norvaline, DFMO and L-ornithine have been tested in the following tests: Forced swimming Test in mice, (Example 1, Example 2), Locomotor Activity Test (Example 3). Locomotor activity of animals was measured using an automated system as described previously (Volke V, Wegener G, Bourin M, Vasar E. Antidepressant- and anxiolytic-like effects of selective neuronal NOS inhibitor l-(2-trifluoromethylphenyl)-imidazole in mice. Behavioural Brain Research 2003; 140: 141-147). Data were analyzed with one-way or two-way analysis of variance (ANOVA) when appropriate. Post hoc comparisons between individual groups were performed by Newman- Keuls test.
- ANOVA analysis of variance
- mice Male C57Bl/6/Bkl mice (Scanbur BK AB, Sweden) weighing 20-25 g were used. Mice were kept 10 per cage (21x37x15 cm) in an animal house at 20 0 C in a 12h light/dark cycle (light on at 7.00 a.m.). Tap water and food pellets were available ad libitum. The animals were kept for at least two weeks in the animal colony before entering experiments. The measurement of locomotor activity, and forced swimming test were carried out consecutively 45 and 55 min after treatment with study compounds, according to Volke V, Wegener G, Bourin M, Vasar E.
- the immobility time was 220 sec in control animals.
- L-ornithine 500 mg/kg did not influence the immobility time (saline 199 sec, L-ornithine 214 sec, Fig 2).
- pre-treatment with L-ornithine antagonised the effect of L-norvaline on immobility time (L-norvaline 127 sec, L-ornithine +L-norvaline 215 sec; p ⁇ 0.001 vs. L-norvaline group).
- arginase inhibitors induced antidepressant-like effect, indicating that both molecules, as well as arginase inhibitors in general, are of interest as therapeutic agents in the treatment and/or prevention of depression and/or depression-related conditions.
- the arginase product L-ornithine was able to block the effect of L-norvaline, further supporting that the antidepressant effect of study compounds are depending on arginase inhibition.
- Locomotor activity was measured using an automated system with six chambers (45x45x45 cm) made from transparent acrylic (MOTI, Technical & Scientific Equipment GMBH, Germany; Volke V, Wegener G, Bourin M, Vasar E. Antidepressant- and anxiolytic-like effects of selective neuronal NOS inhibitor l-(2-trifluoromethylphenyl)-imidazole in mice. Behavioural Brain Research 2003; 140: 141-147). The apparatus-na ⁇ ve mice were put into the chamber, and vertical and horizontal activity was counted during a 10 min. test period. Results:
- DFMO Difluoromethylornithine
- L-norvaline has been shown as a candidate for the treatment and/or prevention of depression and/or depression-related conditions. Accordingly, L-norvaline, DFMO and other compounds with arginase inhibiting activity can be considered as candidates for producing a human medicine for treatment and/or prevention of depression and/or depression-related conditions. Respectively, L-norvaline, DFMO and other compounds with arginase inhibiting activity can be considered as candidates for producing a veterinary medicine for treatment and/or prevention of depression and/or depression-related conditions.
- a method for treating or preventing depression and/or depression-related conditions by administering a mammal a pharmaceutical composition comprising a compound, which exhibits arginase inhibiting activity is hereby disclosed. It is now obvious for one skilled in the art, that other compounds, which exhibit arginase inhibiting activity, may also be useful for treatment and/or prevention of depression and/or depression-related conditions.
- a method for identifying a compound suitable for treatment and/or prevention of depression and/or depression-related conditions comprises determining whether the compound under investigation exhibits arginase inhibiting activity, and if the named compound exhibits arginase inhibiting activity, then the named compound is selected as candidate for a compound suitable for the treatment and/or prevention the named diseases and/or conditions.
- kits for selecting novel compounds for treatment and/or prevention of depression and/or depression-related conditions comprises at least a means for determining a compound's arginase inhibiting activity by a method known to a person skilled in the art.
- This means involves a biochemical assay, wherein the production of L-ornithine or urea is measured, but is not limited to.
- the assay is performed in vitro on purified enzyme arginase, or in a cell culture or in another model system. If arginase inhibiting activity is detected, then the compound is selected for a further screening of its properties as a drug candidate for the treatment and/or prevention of depression and/or depression-related conditions.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The subjects of the current invention are compounds, which exhibit arginase inhibiting activity (including difluoromethylornithine (DFMO) and L-norvaline, but not limited to them), and which can be used as therapeutically active agents for the treatment and prevention of depression and/or depression-related conditions. Other subjects of the present invention are the use of said arginase inhibiting compounds as therapeutically active agents for the manufacture of pharmaceutical compositions for human and veterinary application, pharmaceutical composition comprising said arginase inhibiting compound and a method for treatment and prevention of depression and/or depression-related conditions. Also, a method for identifying compounds suitable for use as therapeutically active agents for treatment and/or prevention of depression and/or depression-related conditions is disclosed. The invention further comprises a kit for selecting compounds for treatment and/or prevention of depression and/or depression-related conditions.
Description
ARGINASE INHIBITORS FOR THE TREATMENT OF DEPRESSION
FIELD OF INVENTION
The present invention relates to compositions useful in the therapy of depression and depression-related conditions. More particularly the invention relates to compounds, which exhibit arginase inhibiting activity.
BACKGROUND OF THE INVENTION
Arginase (EC Nr 3.5.3.1) is an enzyme, activity of which results in converting the amino acid L-arginine into L-ornithine and urea, being an essential part of the urea cycle. In addition to being metabolized to L-ornithine, L-arginine is also a precursor of NO, a free radical molecule involved in a wide range of biological processes. Several compounds useful for the treatment of a variety of diseases and disorders have been also shown as possessing arginase inhibiting activity. E.g. arginase inhibitors N(omega)- hydroxy-L-arginine (NOHA), N'-hydroxy-nor-L-arginine (nor-NOHA), 2 (S)-amino-6- boronohexanoic acid (ABH), S- (+)-Amino-6-iodoacetamidohexanoic acid, S- (+)-Amino-5- iodoacetamidopentanoic acid, L-norvaline, or L-HOArg have been shown as a possible means for treatment of asthma, pulmonary hypertension and sickle cell disease (WO/2004/073623 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions).
L-norvaline is considered to be a potent arginase inhibitor (Rognstad R. Sources of ammonia for urea synthesis in isolated rat liver cells. Biochim Biophys Acta 1977; 496: 249-254; Chang CI, Liao JC, Kuo L. Arginase modulates nitric oxide production in activated macrophages. Am J Physiol 1998; 274: H342-H348). Alpha-DFMO is well-known as an inhibitor of ornithine decarboxylase, but is also a potent inhibitor of arginase (Selamnia M, Mayeur C, Robert V,
Blachier F. Alpha-difluoromethylornithine (DFMO) as a potent arginase activity inhibitor in human colon carcinoma cells. Biochem Pharmacol 1998; 55: 1241-1245.3) The use of alfa-DFMO (eflornithine, sometimes called "elfornithine") is known and has been described alone or in combination with other compounds in US6573290 for the treatment or prevention of cancer (DFMO and celecoxib in combination for cancer chemoprevention and therapy), US6258845 (DFMO and sulindac combination in cancer chemoprevention) and US4925835 (Aziridinyl putrescine containing compositions and their uses in treating prostate cancer), US627741 1 (Pharmaceutical formulation containing DFMO for the treatment of cancer). Norvaline is an analog of the branched chain amino acid valine and is not present among the 20 common natural amino acid compounds of proteins. It has been used in various combinations in research work being included into peptides, as well as in nutritional compositions, e.g. in WO/2008/067641 (Composition for improving blood flow in working muscles comprising L-arginine, Crataegus extract and artichoke flavonoids). It has been demonstrated, that increased activity of arginase results in a diminished output of NO (Que LG, George SE, Gotoh T, Mori M, Huang YC. Effects of arginase isoforms on NO production by nNOS. Nitric Oxide 2002; 6: 1-8.) Thus, arginase inhibitors may increase the production of NO. As NO synthase inhibitors possess antidepressant and anxiolytic like properties (Volke V, Wegener G, Bourin M, Vasar E. Antidepressant- and anxiolytic-like effects of selective neuronal NOS inhibitor l-(2-trifluoromethylphenyl)-imidazole in mice. Behavioural Brain Research 2003; 140: 141-147), arginase inhibitors should have the opposite effect. Surprisingly, as we demonstrate in the following invention, arginase inhibitors possess antidepressant properties. Hereby a new potent and surprising effect of two structurally distinct arginase inhibitors DFMO and L-norvaline has been disclosed leading to the perspective to use compounds with arginase inhibiting activity in the treatment and/or prevention of depression and/or depression- related conditions.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 Effect of imipramine (15 mg/kg), L-norvaline, and DFMO in the forced swimming test (n=8 per group). Results are expressed as mean ± S.E.M. *-P< 0.01, **- P< 0.001, versus saline.
Fig.2 Effect of L-ornithine (500 mg/kg), L-norvaline (500mg/kg), and their combination in the forced swimming test (n=10 per group). Results are expressed as mean ± S.E.M. *-P<
0.01 vs. saline+saline group; #- P< 0.001, vs. SaI+ L-norvaline group.
DISCLOSURE OF THE INVENTION
It has now been found that arginase inhibitors, e.g., L-norvaline and alpha-DFMO are therapeutically promising as antidepressant agents.
The subjects of the current invention are compounds, which exhibit arginase inhibiting activity (including difluoromethylornithine (DFMO) and L-norvaline, but not limited to them), and which therefore can be used as therapeutically active agents for the treatment and prevention of depression and/or depression-related conditions. The compounds inhibiting arginase activity can be difluoromethylornithine (DFMO), L- norvaline, but not limited to them.
Other subjects of the present invention are: the use of said arginase inhibiting compounds as therapeutically active agents for the manufacture of pharmaceutical compositions for human and veterinary application; and pharmaceutical compositions comprising said compounds and pharmaceutically acceptable carrier. Representatives of such carriers are generally known in the human and veterinary pharmaceutical field. Examples of such carriers are starch, alginates, stearates, gelatin, lactose, microcrystalline cellulose, etc. The pharmaceutical compositions may have any form suitable for its application, for instance they may be in the form of capsule, powder, tablet, solution, suspension, lotion, etc. Thus, difluoromethylornithine (DFMO), L-norvaline or other arginase inhibitors can be used as therapeutically active agents for manufacturing pharmaceutical compositions for human and veterinary application. The pharmaceutical compositions comprising difluoromethylornithine (DFMO), L-norvaline or other arginase inhibitors can be used for treatment and/or prevention of depression and/or depression-related conditions.
Also, a method for identifying compounds suitable for use as therapeutically active agents for treatment and/or prevention of depression and/or depression-related conditions and/or anxiety is disclosed, which comprises determining whether the compound under investigation exhibits arginase inhibiting activity, and if the named compound exhibits arginase inhibiting activity, then the named compound is selected as candidate for a compound suitable for use as therapeutically active agent for treatment and/or prevention the named diseases and/or conditions.
Also included in the invention is a method for treatment and prevention of depression and/or depression-related conditions, which comprises administering to a mammal suffering from depression and/or depression-related conditions or a mammal supposed to gain depression or depression related disorder a therapeutically effective amount of a compound which exhibits arginase inhibiting activity.
Moreover, a kit for selecting novel compounds for treatment and/or prevention of depression and/or depression-related conditions is disclosed. This kind of kit comprises at least a means for determining a compound's arginase inhibiting activity by a method known to the person skilled in the art. If arginase inhibiting activity is detected, then the compound is selected for a further screening of its properties as a drug candidate for the treatment and/or prevention of depression and/or depression-related conditions.
DESCRIPTION OF EMBODIMENTS
The antidepressant properties of arginase inhibiting agents L-norvaline and DFMO were investigated by means of a set of behavioural tests in animals conventionally employed in pharmacology and generally considered predictive of antidepressant activity in man (Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977; 229: 327-336; Crawley J, Goodwin FK.
L-norvaline, DFMO and L-ornithine have been tested in the following tests: Forced Swimming Test in mice, (Example 1, Example 2), Locomotor Activity Test (Example 3). Locomotor activity of animals was measured using an automated system as described previously (Volke V, Wegener G, Bourin M, Vasar E. Antidepressant- and anxiolytic-like effects of selective neuronal NOS inhibitor l-(2-trifluoromethylphenyl)-imidazole in mice. Behavioural Brain Research 2003; 140: 141-147).
Data were analyzed with one-way or two-way analysis of variance (ANOVA) when appropriate. Post hoc comparisons between individual groups were performed by Newman- Keuls test.
Example 1. Forced Swimming Test
Male C57Bl/6/Bkl mice (Scanbur BK AB, Sweden) weighing 20-25 g were used. Mice were kept 10 per cage (21x37x15 cm) in an animal house at 200C in a 12h light/dark cycle (light on at 7.00 a.m.). Tap water and food pellets were available ad libitum. The animals were kept for at least two weeks in the animal colony before entering experiments. The measurement of locomotor activity, and forced swimming test were carried out consecutively 45 and 55 min after treatment with study compounds, according to Volke V, Wegener G, Bourin M, Vasar E. Antidepressant- and anxiolytic-like effects of selective neuronal NOS inhibitor l-(2-trifluoromethylphenyl)-imidazole in mice. Behavioural Brain Research 2003; 140: 141-147. In a separate experiment arginase product L-ornithine or saline was injected 15 min prior to L-norvaline.
The Forced Swimming test was performed as described by Porsolt et al Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977; 229: 327-336. A glass cylinder with a diameter of 12 cm was filled with 8 cm water at 25 °C. An animal was put into the water and its behaviour was videotaped during 6 min. An observer blind to treatment protocol counted the immobility time during the last 4 min of the 6 min test. Results:
The immobility time was 220 sec in control animals. L-norvaline given intraperitoneal Iy (i.p.) in the doses of 20, 100 and 500 mg/kg decreased the immobility time to 146, 107 and 96 sec, respectively (Fig 1).
In a separate experiment DFMO (400 mg/kg, i.p.) decreased the immobility time from 219 sec to 191 sec. Lower doses of DFMO (10-100 mg/kg, i.p.) were ineffective. Both L-norvaline and DFMO reduce the immobility time, thus exhibiting an antidepressant- like effect.
Example 2. Effect of L-ornithine, L-norvaline, and their combination in forced swimming test
In a separate experiment L-ornithine (500 mg/kg) did not influence the immobility time (saline 199 sec, L-ornithine 214 sec, Fig 2). However, pre-treatment with L-ornithine antagonised the effect of L-norvaline on immobility time (L-norvaline 127 sec, L-ornithine +L-norvaline 215 sec; p<0.001 vs. L-norvaline group).
Thus, two structurally distinct arginase inhibitors induced antidepressant-like effect, indicating that both molecules, as well as arginase inhibitors in general, are of interest as therapeutic agents in the treatment and/or prevention of depression and/or depression-related conditions. Moreover, the arginase product L-ornithine was able to block the effect of L-norvaline, further supporting that the antidepressant effect of study compounds are depending on arginase inhibition.
Example 3. Effect of L-ornithine, L-norvaline, and their combination on locomotor activity
Locomotor activity was measured using an automated system with six chambers (45x45x45 cm) made from transparent acrylic (MOTI, Technical & Scientific Equipment GMBH, Germany; Volke V, Wegener G, Bourin M, Vasar E. Antidepressant- and anxiolytic-like effects of selective neuronal NOS inhibitor l-(2-trifluoromethylphenyl)-imidazole in mice. Behavioural Brain Research 2003; 140: 141-147). The apparatus-naϊve mice were put into the chamber, and vertical and horizontal activity was counted during a 10 min. test period. Results:
The study compounds either alone or in combination did not change the ambulation of animals, excluding the possibility that the drug effects in the forced swimming test were of non-specific origin.
The descriptions above lead to the conclusion that compounds exposing arginase inhibiting activity can be used as pharmacological agents for treating and/or preventing of depression and/or depression-related conditions. Difluoromethylornithine (DFMO) has been shown as a candidate for the treatment and/or prevention of depression and/or depression-related conditions. L-norvaline has been shown as a candidate for the treatment and/or prevention of depression and/or depression-related conditions. Accordingly, L-norvaline, DFMO and other
compounds with arginase inhibiting activity can be considered as candidates for producing a human medicine for treatment and/or prevention of depression and/or depression-related conditions. Respectively, L-norvaline, DFMO and other compounds with arginase inhibiting activity can be considered as candidates for producing a veterinary medicine for treatment and/or prevention of depression and/or depression-related conditions.
A method for treating or preventing depression and/or depression-related conditions by administering a mammal a pharmaceutical composition comprising a compound, which exhibits arginase inhibiting activity is hereby disclosed. It is now obvious for one skilled in the art, that other compounds, which exhibit arginase inhibiting activity, may also be useful for treatment and/or prevention of depression and/or depression-related conditions. Thus, a method for identifying a compound suitable for treatment and/or prevention of depression and/or depression-related conditions comprises determining whether the compound under investigation exhibits arginase inhibiting activity, and if the named compound exhibits arginase inhibiting activity, then the named compound is selected as candidate for a compound suitable for the treatment and/or prevention the named diseases and/or conditions.
One skilled in the art can also conclude, that a kit for selecting novel compounds for treatment and/or prevention of depression and/or depression-related conditions comprises at least a means for determining a compound's arginase inhibiting activity by a method known to a person skilled in the art. This means involves a biochemical assay, wherein the production of L-ornithine or urea is measured, but is not limited to. The assay is performed in vitro on purified enzyme arginase, or in a cell culture or in another model system. If arginase inhibiting activity is detected, then the compound is selected for a further screening of its properties as a drug candidate for the treatment and/or prevention of depression and/or depression-related conditions.
Claims
1. Compounds, which exhibit arginase inhibiting activity for use as therapeutically active agents for treatment and/or prevention of depression and/or depression-related conditions.
2. Compound according to claim 1 , which is difluoromethylornithine (DFMO).
3. Compound according to claim 1 , which is L-norvaline.
4. Use of a compound according to any one of the preceding claims 1 to 3 as therapeutically active agent for manufacturing a pharmaceutical composition for human application.
5. Use of a compound according to any one of the preceding claims 1 to 3 as therapeutically active agent for manufacturing a pharmaceutical composition for veterinary application.
6. A pharmaceutical composition for treatment and/or prevention of depression and/or depression-related conditions comprising a therapeutically active agent and a pharmaceutically acceptable carrier, characterized in that the therapeutically active agent is a compound according to any one of claims 1 to 3.
7. Method for identifying compounds for use as therapeutically active agents for treatment and/or prevention of depression and/or depression-related conditions comprising a) determining whether the compound under investigation exhibits arginase inhibiting activity, b) and if the named compound exhibits arginase inhibiting activity, then the named compound is identified as a compound applicable for use as therapeutically active agent for treatment and/or prevention of depression and/or depression-related conditions.
8. Method for treating and/or preventing of depression and/or depression-related conditions in a mammal in need of such treatment and/or prevention, said method comprising administering to said mammal a therapeutically effective amount of a compound which exhibits arginase inhibiting activity.
9. Method according to claim 8, whereas said compound is difluoromethylornithine (DFMO).
10. Method according to claim 8, whereas said compound is L-norvaline.
1 1. A kit for identifying compounds for use as therapeutically active agents for treatment and/or prevention of depression and/or depression-related conditions, which comprises at least a means for determining a compound's arginase inhibiting activity.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08874946A EP2376072A1 (en) | 2008-12-29 | 2008-12-29 | Arginase inhibitors for the treatment of depression |
| US13/141,992 US20110318271A1 (en) | 2008-12-29 | 2008-12-29 | Arginase Inhibitors for the Treatment of Depression |
| RU2011129717/15A RU2488390C2 (en) | 2008-12-29 | 2008-12-29 | Arginase inhibitors for treating depression |
| PCT/EE2008/000027 WO2010075863A1 (en) | 2008-12-29 | 2008-12-29 | Arginase inhibitors for the treatment of depression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EE2008/000027 WO2010075863A1 (en) | 2008-12-29 | 2008-12-29 | Arginase inhibitors for the treatment of depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2010075863A1 true WO2010075863A1 (en) | 2010-07-08 |
Family
ID=40872357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EE2008/000027 WO2010075863A1 (en) | 2008-12-29 | 2008-12-29 | Arginase inhibitors for the treatment of depression |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20110318271A1 (en) |
| EP (1) | EP2376072A1 (en) |
| RU (1) | RU2488390C2 (en) |
| WO (1) | WO2010075863A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12054500B2 (en) | 2018-03-05 | 2024-08-06 | Arcus Biosciences, Inc. | Arginase inhibitors |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102408399B1 (en) * | 2016-03-08 | 2022-06-13 | 세이지 테라퓨틱스, 인크. | Neuroactive steroids, compositions, and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6387890B1 (en) * | 1997-10-10 | 2002-05-14 | Trustees Of The University Of Pennsylvania | Compositions and methods for inhibiting arginase activity |
| WO2004073623A2 (en) * | 2003-02-14 | 2004-09-02 | Children's Hospital & Research Center At Oakland | Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
| WO2008061612A1 (en) * | 2006-11-21 | 2008-05-29 | Rijksuniversiteit Groningen | Use of arginase inhibitors in the treatment of asthma and allergic rhinitis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1446396A1 (en) * | 2001-11-08 | 2004-08-18 | Sepracor, Inc. | Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram |
| CN1703227A (en) * | 2002-09-27 | 2005-11-30 | 儿童医疗中心有限公司 | Methods and compositions for treatment of neurological disorder |
-
2008
- 2008-12-29 WO PCT/EE2008/000027 patent/WO2010075863A1/en active Application Filing
- 2008-12-29 US US13/141,992 patent/US20110318271A1/en not_active Abandoned
- 2008-12-29 RU RU2011129717/15A patent/RU2488390C2/en not_active IP Right Cessation
- 2008-12-29 EP EP08874946A patent/EP2376072A1/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6387890B1 (en) * | 1997-10-10 | 2002-05-14 | Trustees Of The University Of Pennsylvania | Compositions and methods for inhibiting arginase activity |
| WO2004073623A2 (en) * | 2003-02-14 | 2004-09-02 | Children's Hospital & Research Center At Oakland | Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
| WO2008061612A1 (en) * | 2006-11-21 | 2008-05-29 | Rijksuniversiteit Groningen | Use of arginase inhibitors in the treatment of asthma and allergic rhinitis |
Non-Patent Citations (4)
| Title |
|---|
| CUSTOT J ET AL: "The new [alpha]-amino acid N[omega]-hydroxy-nor-L-arginine: A high-affinity inhibitor of arginase well adapted to bind to its manganese cluster", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY 1997 US, vol. 119, no. 17, 1997, pages 4086 - 4087, XP002540256, ISSN: 0002-7863 * |
| ELGÜN S ET AL: "Increased serum arginase activity in depressed patients.", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY FEB 2000, vol. 24, no. 2, February 2000 (2000-02-01), pages 227 - 232, XP002540257, ISSN: 0278-5846 * |
| MORRIS SIDNEY M JR: "Recent advances in arginine metabolism", CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, RAPID SCIENCE PUBLISHERS, LONDON, GB, vol. 7, no. 1, 1 January 2004 (2004-01-01), pages 45 - 51, XP009120435, ISSN: 1363-1950 * |
| SELAMNIA MOHAMED ET AL: "alpha-Difluoromethylornithine (DFMO) as a potent arginase activity inhibitor in human colon carcinoma cells", BIOCHEMICAL PHARMACOLOGY, vol. 55, no. 8, 15 April 1998 (1998-04-15), pages 1241 - 1245, XP002540255, ISSN: 0006-2952 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12054500B2 (en) | 2018-03-05 | 2024-08-06 | Arcus Biosciences, Inc. | Arginase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2376072A1 (en) | 2011-10-19 |
| RU2488390C2 (en) | 2013-07-27 |
| US20110318271A1 (en) | 2011-12-29 |
| RU2011129717A (en) | 2013-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Harkin et al. | Nitric oxide synthase inhibitors have antidepressant-like properties in mice: 1. Acute treatments are active in the forced swim test | |
| Schousboe et al. | GABA: homeostatic and pharmacological aspects | |
| Tran et al. | Amyloid β‐peptide induces nitric oxide production in rat hippocampus: association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors | |
| Buelna-Chontal et al. | Redox activation of Nrf2 & NF-κB: a double end sword? | |
| Hu et al. | Hydrogen sulfide: neurophysiology and neuropathology | |
| Portwich et al. | Biosynthetic pathway of mycosporines (mycosporine-like amino acids) in the cyanobacterium Chlorogloeopsis sp. strain PCC 6912 | |
| Taksande et al. | Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine | |
| Son et al. | Ginkgetin, a Biflavone from Ginko biloba leaves, inhibits cyclooxygenases-2 and 5-lipoxygenase in mouse bone marrow-derived mast cells | |
| Vrijsen et al. | Polyamines in Parkinson's disease: balancing between neurotoxicity and neuroprotection | |
| Ashraf et al. | Endothelium mediated vasorelaxant response of garlic in isolated rat aorta: role of nitric oxide | |
| Babbedge et al. | Anti‐nociceptive activity of nitric oxide synthase inhibitors in the mouse: dissociation between the effect of l‐NAME and l‐NMMA | |
| US11116747B2 (en) | Compositions comprising proanthocyanidins and oenothein B | |
| Wu et al. | A novel approach to inhibit intracellular vitamin B6‐dependent enzymes: proof of principle with human and plasmodium ornithine decarboxylase and human histidine decarboxylase | |
| Choi et al. | Zeatin prevents amyloid β-induced neurotoxicity and scopolamine-induced cognitive deficits | |
| Kotagale et al. | Agmatine inhibits nicotine withdrawal induced cognitive deficits in inhibitory avoidance task in rats: Contribution of α2-adrenoceptors | |
| NO20081681L (en) | N- [1,3,4] -thiadiazol-2-yl-benzenesulfonamides, process for their preparation and their use as pharmaceuticals | |
| WO1993012775A1 (en) | Pharmaceutical composition and process for the preparation thereof | |
| Pal et al. | Evaluation of oxidative stress and its modulation by L-arginine and L-ascorbic acid in repetitive restraint stress model in Wistar rats | |
| US20110318271A1 (en) | Arginase Inhibitors for the Treatment of Depression | |
| Madsen et al. | Regulation of excitation by GABA neurotransmission: focus on metabolism and transport | |
| Jiang et al. | Effects of AGEs on oxidation stress and antioxidation abilities in cultured astrocytes | |
| Hashimoto | The NMDA receptor hypofunction hypothesis for schizophrenia and glycine modulatory sites on the NMDA receptors as potential therapeutic drugs | |
| Borah et al. | L-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation | |
| Itzhak | Blockade of sensitization to the toxic effects of cocaine in mice by nitric oxide synthase inhibitors | |
| Borah et al. | Long term L-DOPA treatment causes production of 6-OHDA in the mouse striatum: Involvement of hydroxyl radical |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08874946 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2008874946 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2011129717 Country of ref document: RU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 13141992 Country of ref document: US |